Zusammenfassung
Kalziumionen spielen für die Aktivierung von Zellen eine bedeutende Rolle. Ein Kalziumeinstrom in die Zelle ist z. B. für die myokardiale Kontraktion, für die Reizbildung und Reizleitung im Herzen und für die Aufrechterhaltung des Gefäßtonus erforderlich. Die therapeutisch verwendeten Kalziumantagonisten lassen sich in drei chemische Klassen einteilen: Phenylalkylamine (z. B. Verapamil, Gallopamil), Dihydropyridine (Nifidepin, Nitrendipin, Felodipin, Amlodipin u.a.) und Benzothiazepine (Diltiazem). Diese Substanzen unterscheiden sich hinsichtlich ihrer kardiovaskulären Wirkungen und ihrer Pharmakokinetik.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Braunwald E (1982) Mechanism of action of calcium-channel-blocking agents. N Engl J Med 307:1618–1627
Burns ER, Frishman WH (1983) The anti-platelet effects of calcium channel blockers add to their anti-anginal properties. Int J Cardiol 4:372–379
Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41–57
Findling R, Frishman W, Javed MT, Heffer S, Brandt L (1996) Calcium channel blockers and the gastrointestinal tract. Am J Ther 3:383–408
Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol 17:149–166
Fleckenstein A, Kammermeier H, Döring HJ, Freund HJ (1967) On the action mechanism of new coronary dilators with simultaneous oxygen saving myocardial effects, Prenylamine and Iproveratril. Z Kreislaufforsch 56:716–744
Fromm MF (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69–74
Hofmann F, Lacinova L, Klugbauer N (1999) Voltage-dependent calcium channels: from structure to function. Rev Physiol Biochem Pharmacol 139:33–87
Klotz U (2002) Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung 52:155–161
Kohlhardt M, Fleckenstein A (1977) Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 298:267–272
Lacoste L, Lam JY, Hung J, Waters D (1994) Oral verapamil inhibits platelet thrombus formation in humans. Circulation 89:630–634
Lindner E (1960) N-(3-phenylisopropyl)-3,3-diphenylpropylamine, a new substance with a dilating action on the coronary vessels. Part 1: Action on the circulation. Arzneimittelforschung 10:569–573
Miller RJ (1987) Multiple calcium channels and neuronal function. Science 235:46–52
Rosenthal T, Ezra D (1995) Calcium antagonists. Drug interactions of clinical significance. Drug Saf 13:157–187
Schoen RE, Frishman WH, Shamoon H (1988) Hormonal and metabolic effects of calcium channel antagonists in man. Am J Med 84:492–504
Van Breemen C, Mangel A, Fahim M, Meisheri K (1982) Selectivity of calcium antagonistic action in vascular smooth muscle. Am J Cardiol 49:507–510
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Jähnchen, E., Trenk, D. (2004). Kalziumantagonisten. In: Roskamm, H., Neumann, FJ., Kalusche, D., Bestehorn, HP. (eds) Herzkrankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18649-3_45
Download citation
DOI: https://doi.org/10.1007/978-3-642-18649-3_45
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62220-5
Online ISBN: 978-3-642-18649-3
eBook Packages: Springer Book Archive